The forecasted number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Japan is stable from 2024 through 2028, with consistent values reported. In 2023, the actual count stood at 82 cases. For 2024, the forecast begins at 82 cases, with subsequent years leveling at 81 cases annually from 2025 to 2028.
Year-on-year variations indicate a minor decrease from 2023 to 2025, with a 1.22% reduction, followed by stabilization. Over the five-year forecast period from 2024 to 2028, the Compound Annual Growth Rate (CAGR) is essentially zero, reflecting the steadiness of projections.
Future trends to watch for:
- Potential impacts of new TB treatment advancements.
- Changes in public health policy or healthcare practices affecting RR-/MDR-TB.
- Any emerging data on regional outbreaks or containment efforts.
